FindTrial
Sign In

Inhibition of ovarian cancer stem cells by luteolin targeting the KDM4C/PPP2CA/YAP pathway: an in vitro observational clinical study

Inhibition of ovarian cancer stem cells by luteolin targeting the KDM4C/PPP2CA/YAP pathway: an in vitro observational clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056567
Enrollment
Unknown
Registered
2022-02-08
Start date
2022-02-08
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Luteolin group:None
Solvent group:None

Sponsors

Affiliated Cancer Hospital of Chongqing University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients with newly diagnosed stage III-IV ovarian cancer; 2. Histologically confirmed high-grade serous ovarian cancer with ascites; 3. Preoperative evaluation should be performed (and planned by the patient) with abdominal puncture to extract ascites or tumor tissue resection; 4. Informed consent for clinical study has been signed.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Initial activation level of KDM4C/PPP2CA/YAP pathway in ovarian cancer stem cells;Inhibitory ability of luteolin on ovarian cancer stem cells;Activation level of PPP2CA/KDM4C/YAP signaling pathway in ovarian cancer stem cells treated after luteolin;Correlation between the inhibitory ability of luteolin on ovarian cancer stem cells and the inhibitory level of KDM4C/PPP2CA/YAP pathway;—

Countries

China

Contacts

Public ContactLang Tingyuan

Affiliated Cancer Hospital of Chongqing University

michaellang2009@163.com+86 18717859346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026